Biosimilar of pegfilgrastim

01/2020

MUDr. Viktor Maňásek

Komplexní onkologické centrum, Nemocnice Nový Jičín

SUMMARY

Chemotherapy-induced neutropenia, and in particular febrile neutropenia, is a serious complication of antitumor systemic therapy. It is possible to indicate the growth factors of myelopoiesis in prophylaxis of neutropenia in specific situations. In addition to filgrastim and pegfilgrastim, a number of biosimillar products have recently been developed with a similar therapeutic and safety profile as compared to the original products. Biosimillar drugs are subject to the same approval processes and the same standards of pharmaceutical quality, safety and efficacy that apply to all biological drugs approved in the European Union. Reducing the cost of biosimilar preparations could optimize the use of growth factors with better availability for indicated patients.

Key words

neutropenia, pegfilgrastim, biosimilars